This study follows 94 patients, age 45 to 60, by controlled, random and prospective studies in time period of six months. Out of total number of patients, 53 were divided into research group and treated with hormonal therapy (2 mg of estradiol and 0,5 mg of norgestrel), 41 patients were divided into control group and treated with refemin (Cimicifuga recemosa). Results were statistically processed using Student test and ANOVA, giving us following results: use of HNL resulted with statistically significant changes--increase of heart frequency (*p<0,01), QTc-intervals (**p=0,01), increase of systolic pressure (**p=0,01), increase of diastolic pressure (**p=0,01), increase of body mass index (**p=0,01), endometrial thickness decrease (**p=0,01); use of Cimicifuge recemose resulted with statistically significant changes--increase of diastolic pressure(*p=0,01), increase of body mass index (BMI) (*p=0,01) and endometrial thickness decrease (*p=0,05). By testing research and controlled group with ANOVA test, we have determined that there is statistical difference in operating between recovered hormone therapy and Cimicifuge recemose within parameters of hearth frequency and diastolic pressure.
Download full-text PDF |
Source |
---|
PLoS One
January 2025
Department of Pain Medicine, Aichi Medical University, Nagakute, Aichi, Japan.
Background: Lowering barometric pressure (LP) can exacerbate neuropathic pain. However, animal studies in this field are limited to a few conditions. Furthermore, although sympathetic involvement has been reported as a possible mechanism, whether the sympathetic nervous system is involved in the hypothalamic-pituitary-adrenal (HPA) axis remains unknown.
View Article and Find Full Text PDFPLoS One
January 2025
School of Human Nutrition, McGill University, Montreal, Québec, Canada.
Objective: Managing blood glucose levels is challenging for elite athletes with type 1 diabetes (T1D) as competition can cause unpredictable fluctuations. While fear of hypoglycemia during physical activity is well documented, research on hyperglycemia-related anxiety (HRA) is limited. HRA refers to the heightened fear that hyperglycemia-related symptoms will impair functioning.
View Article and Find Full Text PDFBJOG
January 2025
Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Nijmegen, The Netherlands.
Objective: To compare menopause-related quality of life (QoL) after risk-reducing salpingectomy (RRS) versus risk-reducing salpingo-oophorectomy (RRSO) until 3 years of post-surgery.
Design: A prospective study (TUBA study) with treatment allocation based on patients' preference. Data were collected pre-surgery and at 3 months, 1 and 3 years of post-surgery.
Dose Response
January 2025
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Cytokinins are plant hormones that regulate cell growth and differentiation. In particular, zeatin (ZTN) delays cellular senescence of human fibroblasts and keratinocytes and exhibits anticancer activity. Chemotherapy-induced anemia is a major side effect of anticancer therapy secondary to premature senescence of red blood cells (RBCs).
View Article and Find Full Text PDFGland Surg
December 2024
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background: To date, the overall survival (OS) of hormone receptor-positive advanced breast cancer (ABC) treated with palbociclib has not been reported in Chinese patients. It still remains unclear what kind of patients may benefit in OS from palbociclib treatment and what the optimal sequential antineoplastic regimen is for those progressing on palbociclib. Therefore, we aimed to investigate the OS outcome of ABC patients receiving palbociclib, establish a predictive model to identify the potential candidates who may benefit from palbociclib and explore the ideal subsequent treatment strategy after palbociclib.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!